文献速递胸部肿瘤

胸部肿瘤影像学二十年进展:从解剖成像到多参数精准评估

Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective.
PubMed 文献 · J Thorac Oncol · 2026-01-01

该综述回顾近20年胸部肿瘤影像学进展:CT向多探测器、双能及光子计数演进,PET/CT成为分期与放疗计划核心,MRI功能序列与PET/MRI、诊疗一体化平台拓展应用,影像组学与人工智能推动精准医学,但标准化与验证仍是挑战。

要点

  • CT技术升级提升空间分辨率、降低辐射剂量并实现碘图功能评估。
  • 18F-FDG PET/CT是分期、放疗计划与疗效评估的关键工具。
  • 影像组学与人工智能可预测预后、疗效及分子特征,但需标准化验证。

核心结论

  • 胸部影像已从解剖可视化演进为整合功能、定量与人工智能的多参数评估,成为胸部肿瘤精准医学的基石。

研究设计与样本

  • 本文为胸部肿瘤影像学20年进展综述,未报告系统检索范围与样本量。

主要发现

  • 多探测器CT、双能CT和光子计数CT提高了空间分辨率、降低了辐射剂量,并通过碘图实现功能评估。
  • 18F-FDG PET/CT在分期、放疗计划和疗效评估中不可或缺,靶向缺氧、增殖和免疫生物标志物的新型示踪剂拓展了其临床用途。
  • MRI新序列改善了时间分辨率,弥散加权成像和动态对比增强等功能技术支持早期疗效评估和影像基因组学探索。
  • PET/MRI和诊疗一体化平台体现了诊断与治疗的融合,支持个性化肿瘤诊疗。
  • 影像组学和影像基因组学提取高维影像特征预测预后、治疗反应和分子谱,人工智能加速检测、分割和风险分层,性能可与专家判读媲美。

临床怎么用

  • 可将CT功能成像、PET/CT新型示踪剂、MRI功能序列及影像组学/人工智能工具整合用于胸部肿瘤的早期检测、分期、放疗计划和疗效评估。

局限性

  • 影像组学与人工智能方法在标准化和验证方面仍面临挑战。
  • 将上述创新转化为常规临床实践仍需多学科协作和严谨的方法学框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the critical role of imaging in early detection, staging, and treatment planning. In the past 2 decades, thoracic imaging has evolved from anatomical visualization to multiparametric assessment integrating functional, quantitative, and artificial intelligence-driven applications. Advances in computed tomography (CT), including multidetector arrays, dual-energy CT, and photon-counting CT, have improved spatial resolution, reduced radiation dose, and enabled functional evaluation through iodine mapping. Positron emission tomography/CT (PET/CT), particularly with Fluorine-18 fluorodeoxyglucose-PET/CT, has become indispensable for staging, radiotherapy planning, and response assessment, whereas novel tracers targeting hypoxia, proliferation, and immune biomarkers expand its clinical utility. Magnetic resonance imaging inherently offers superior soft tissue contrast, with new imaging sequences improving prior limited temporal resolution, and more recent functional techniques such as diffusion-weighted imaging and dynamic contrast enhancement, supporting early response evaluation and radiogenomic exploration. Hybrid modalities such as PET/magnetic resonance imaging and theranostic platforms exemplify the convergence of diagnosis and therapy, enabling personalized oncology. Radiomics and radiogenomics extract high-dimensional imaging features to predict prognosis, treatment response, and molecular profiles, whereas artificial intelligence accelerates detection, segmentation, and risk stratification with performance metrics rivaling expert interpretation. Despite challenges in standardization and validation, these innovations position imaging as a cornerstone of precision medicine in thoracic oncology. Continued multidisciplinary collaboration and rigorous methodological frameworks will be essential to translate these advances into routine clinical practice.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Erasmus JJ, Vlahos I. Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective. J Thorac Oncol. 2026. PMID: 42108076. doi:10.1016/j.jtho.2026.103563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。